1). Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348:1546–54.
Article
2). Brun-Buisson C, Meshaka P, Pinton P, Vallet B; EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 2004; 30:580–8.
3). Rosser CJ, Bare RL, Meredith JW. Urinary tract infections in the critically ill patient with a urinary catheter. Am J Surg. 1999; 177:287–90.
Article
4). Lu PL, Liu YC, Toh HS, Lee YL, Liu YM, Ho CM, et al. Epidemiology and antimicrobial susceptibility profiles of gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009–2010 results from the study for monitoring antimicrobial resistance trends (SMART). Int J Antimicrob Agents. 2012; 40:S37–43.
Article
5). Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the study for monitoring antimicrobial resistance trends (SMART) program, 2007. Antimicrob Agents Chemother. 2009; 53:3280–4.
6). Frakking FN, Rottier WC, Dorigo-Zetsma JW, van Hattem JM, van Hees BC, Kluytmans JA, et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β -lactamase-producing bacteria. Antimicrob Agents Chemother. 2013; 57:3092–9.
7). Lin HC, Lai LA, Wu JY, Su YM, Chang SP, Hsueh YM. Risk factors for acquiring extended-spectrum β -lactamase-producing Enterobacteriaceae in geriatric patients with multiple comorbidities in respiratory care wards. Geriatr Gerontol Int. 2013; 13:663–71.
8). Park SH, Choi SM, Lee DG, Kim J, Choi JH, Kim SH, et al. Emergence of extended-spectrum β -lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes. Microb Drug Resist. 2011; 17:537–44.
9). Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruíz M, Peña C, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010; 50:40–8.
10). Ku NS, Kim YC, Kim MH, Song JE, Oh DH, Ahn JY, et al. Risk factors for 28-day mortality in elderly patients with extended-spectrum β -lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia. Arch Gerontol Geriatr. 2014; 58:105–9.
11). Nicolle LE. Urinary tract infection. Crit Care Clin. 2013; 29:699–715.
Article
12). Hayakawa K, Gattu S, Marchaim D, Bhargava A, Palla M, Alshabani K, et al. Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β -lactamase in a large U.S. medical center. Antimicrob Agents Chemother. 2013; 57:4010–8.
13). Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000–2009). BMC Infect Dis. 2013; 13:19.
Article
14). Calandra T, Cohen J. International Sepsis Forum Definition of Infection in the ICU Consensus Conference: The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005; 33:1538–48.
15). Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39:165–228.
Article
16). Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Healthcare--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002; 137:791–7.
17). Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement M100-S17. Wayne, PA: CLSI;2007.
18). The Korean Society of Infectious Diseases; The Korean Society for Chemotherapy; Korean Association of Urogenital Tract Infection and Inflammation; The Korean Society of Clinical Microbiology. Clinical guideline for the diagnosis and treatment of urinary tract infections: asymptomatic bacteriuria, uncomplicated & complicated urinary tract infections, bacterial prostatitis. Infect Chemother. 2011; 43:1–25.
19). Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, Domínguez-Gil González M, Gómez-Nieto A, Palacios-Martín T, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract. 2012; 66:891–6.
Article
20). Sader HS, Flamm RK, Jones RN. Frequency of occurrence and antimicrobial susceptibility of gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009–2011). J Chemother. 2014; 26:133–8.
Article
21). Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000–2009. Infect Control Hosp Epidemiol. 2013; 34:940–6.
Article
22). Lin JN, Chen YH, Chang LL, Lai CH, Lin HL, Lin HH. Clinical characteristics and outcomes of patients with extended-spectrum β -lactamase-producing bacteremias in the emergency department. Intern Emerg Med. 2011; 6:547–55.
23). Lye DC, Earnest A, Ling ML, Lee TE, Yong HC, Fisher DA, et al. The impact of multidrug resistance in healthcare-associated and nosocomial gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect. 2012; 18:502–8.
Article
24). Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009–2010. Diagn Microbiol Infect Dis. 2011; 70:507–11.
Article
25). Jean SS, Hsueh PR, Lee WS, Chang HT, Chou MY, Chen IS, et al. Nationwide surveillance of antimicrobial resistance among Enterobacteriaceae in intensive care units in Taiwan. Eur J Clin Microbiol Infect Dis. 2009; 28:215–20.
Article
26). Azap OK, Arslan H, Serefhanoğlu K, Colakoğlu S, Erdoğan H, Timurkaynak F, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2010; 16:147–51.
27). Lee DS, Lee CB, Lee SJ. Prevalence and risk factors for extended spectrum beta-lactamase-producing uropathogens in patients with urinary tract infection. Korean J Urol. 2010; 51:492–7.
Article
28). Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β -lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012; 67:1311–20.
29). Rodríguez-Baño J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther. 2008; 6:671–83.
30). Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004; 48:4574–81.
31). Kang CI, Kim SH, Bang JW, Kim HB, Park SW, Choe YJ, et al. Risk factors for infection and treatment outcome of bloodstream infections due to extended spectrum beta-lactamases producing Klebsiella pneumoniae. Infect Chemother. 2003; 35:61–70.
32). Park SH, Choi SM, Chang YK, Lee DG, Cho SY, Lee HJ, et al. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β -lactamase-producing Escherichia coli. J Antimicrob Chemother. 2014; 69:2848–56.
33). Chang R, Greene MT, Chenoweth CE, Kuhn L, Shuman E, Rogers MA, et al. Epidemiology of hospital-acquired urinary tract-related bloodstream infection at a university hospital. Infect Control Hosp Epidemiol. 2011; 32:1127–9.
Article
34). Menashe G, Borer A, Yagupsky P, Peled N, Gilad J, Fraser D, et al. Clinical significance and impact on mortality of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis. 2001; 33:188–93.
35). Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect. 2002; 52:99–106.
36). Wang F, Wu Y, Tang L, Zhu W, Chen F, Xu T, et al. Brain natriuretic peptide for prediction of mortality in patients with sepsis: a systematic review and meta-analysis. Crit Care. 2012; 16:R74.
Article
37). Hur M, Kim H, Lee S, Cristofano F, Magrini L, Marino R, et al. Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis. BMC Infect Dis. 2014; 14:224.
Article